Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.37 |
| ▸ | ITGAV | P06756 | 1/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.37 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.37 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3063046 | 0.90 | CTSK (0.42) | CTSKCTSSMAPTMEN1KMT2A | |
| SCHEMBL2923386 | 0.86 | CTSK (0.46) | CTSKCTSSMAPTACEPPARG | |
| SCHEMBL2922464 | 0.82 | TSHR (0.44) | MAPTPOLB | |
| SCHEMBL2921342 | 0.81 | ACE (0.56) | CTSKCTSSACEMEN1KMT2A | |
| SCHEMBL2921337 | 0.81 | ACE (0.56) | CTSKCTSSACEMEN1KMT2A | |
| SCHEMBL2926756 | 0.78 | P2RY12 (0.42) | — | |
| SCHEMBL16263882 | 0.78 | CTSK (0.46) | CTSKCTSSMAPTPOLBPPARG | |
| SCHEMBL27793713 | 0.78 | MEN1 (0.38) | MAPTMEN1KMT2APOLB | |
| SCHEMBL2923417 | 0.77 | CTSK (0.45) | CTSKCTSSACEMEN1KMT2A | |
| SCHEMBL2927031 | 0.77 | CTSK (0.45) | CTSKCTSSACEMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518912-B2 | Phosphonic acid derivates and their use as P2Y12 receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-08-27 | — | — | US | disclosed |
| EP-2225253-B1 | PHOSPHONIC ACID DERIVATES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-06-27 | — | — | EP | disclosed |
| US-20100261678-A1 | PHOSPHONIC ACID DERIVATES AD THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | VIATRIS ASIA PACIFIC PTE. LTD. (SG) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261678-A1 | PHOSPHONIC ACID DERIVATES AD THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | P2RY12, P2RY13, P2RY11 | CTSK 4627/4885CTSS 4636/4885MAPT 1762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.